Venn Life Sciences, a European CRO, has entered into an agreement to acquire the entire issued share capital of Kinesis Pharma, a Netherlands-based provider of specialist consultancy services around the chemical-pharmaceutical, nonclinical and early clinical development of drug products, for a total maximum consideration of up to $7.3 million (€6.5 million).

The acquisition is in line with the company’s strategy of making targeted, complementary acquisitions that improve the group’s geographical coverage and deepen its service capability, in order to create a highly differentiated European CRO.